<DOC>
	<DOCNO>NCT02501096</DOCNO>
	<brief_summary>This open-label Phase 1b/2 trial lenvatinib ( E7080 ) plus pembrolizumab participant select solid tumor . Phase 1b determine confirm maximum tolerate dose ( MTD ) lenvatinib combination 200 milligram ( mg ) ( intravenous [ IV ] , every 3 week [ Q3W ] ) pembrolizumab participant select solid tumor ( i.e . non-small cell lung cancer , renal cell carcinoma , endometrial carcinoma , urothelial carcinoma , squamous cell carcinoma head neck , melanoma ) . Phase 2 ( Expansion ) evaluate safety efficacy combination 6 cohort MTD Phase 1b ( lenvatinib 20 mg/day orally + pembrolizumab 200 mg Q3W , IV ) .</brief_summary>
	<brief_title>Phase 1b/2 Trial Lenvatinib ( E7080 ) Plus Pembrolizumab Subjects With Selected Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Lenvatinib</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>1 . Phase 1b : Histologically and/or cytologically confirm metastatic select solid tumor type progress treatment approve therapy standard effective therapy available . If nivolumab pembrolizumab approve therapy participant 's tumor type , participant treat , Investigator may enroll participant study . Phase 2 : Up two prior line systemic therapy select tumor type describe ( unless discuss sponsor ) For nonsmall cell lung cancer ( NSCLC ) melanoma cohort , participant must progress prior treatment one antiPD1 , antiPDL1 , antiPDL2 agent Selected tumor type phase : NSCLC , predominantly clear cell renal cell carcinoma , endometrial carcinoma , urothelial carcinoma , squamous cell carcinoma head neck , melanoma ( exclude uveal melanoma ) 2 . Life expectancy 12 week 3 . Phase 2 : Measurable disease meeting follow criterion : 1 . At least 1 lesion great equal 10 mm long diameter nonlymph node great equal 15 mm shortaxis diameter lymph node serially measurable accord irRECIST ( immunerelated RECIST ) use computerize tomography/magnetic resonance imaging ( CT/MRI ) 2 . Lesions external beam radiotherapy ( EBRT ) locoregional therapy radiofrequency ( RF ) ablation must show subsequent evidence substantial size increase deem target lesion 4 . Participants must Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 5 . Adequately control blood pressure ( BP ) without antihypertensive medication , define BP le equal 150/90 mmHg screen change antihypertensive medication within 1 week prior Cycle 1 Day 1 6 . Adequate renal function define creatinine le equal 1.5 X ULN ( upper limit normal ) calculate creatinine clearance great equal 40 mL/min per Cockcroft Gault formula creatinine level great 1.5 X ULN 7 . Adequate bone marrow function : 1 . Absolute neutrophil count ( ANC ) great equal 1500/mm3 ( great equal 1.5 X 103/uL ) 2 . Platelets great equal 100,000/mm3 ( great equal 100 X 109/L ) 3 . Hemoglobin great equal 9.0 g/dL 8 . Adequate blood coagulation function evidence International Normalized Ratio ( INR ) less equal 1.5 9 . Adequate liver function evidence bilirubin less equal 1.5 time ULN alkaline phosphatase ( ALP ) , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) less equal 3 X ULN ( case liver metastases less equal 5 X ULN ) . In case ALP great 3 X ULN ( absence liver metastasis ) great 5 X ULN ( presence liver metastasis ) AND participant also know bone metastasis , liver specific ALP must separate total use ass liver function instead total ALP 10 . Males females age great equal 18 year time inform consent 11 . Participants know brain metastasis eligible complete primary brain therapy ( whole brain radiotherapy , stereotactic radiosurgery , complete surgical resection ) remain clinically stable , asymptomatic , steroid least 28 day 12 . All female must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit betahuman chorionic gonadotropin [ BhCG ] ) Screening Visit Baseline Visit . A pregnancy test need perform within 72 hour first dose study drug . Females childbearing potential , practice total abstinence vasectomize partner confirm azoospermia , must agree use two highly effective method contraception , eg , 1 ) intrauterine device [ IUD ] , intrauterine system ( IUS ) ; 2 ) barrier method condom occlusive cup ( diaphragm cervical/vault cap ) + spermicide ( foam , gel , cream , etc . ) ; 3 ) oral , inject , implanted hormonal contraceptive throughout entire study period 30 day study treatment discontinuation . Use doublebarrier method ( ie , use time condom + occlusive cup [ diaphragm cervical/vault cap ] + spermicide [ foam , gel , cream , etc . ] ) accept two highly effective method contraception . The participant exempt requirement postmenopausal woman ( defined woman amenorrheic least 12 consecutive month , appropriate age group , without know suspected primary cause ) participant sterilize surgically otherwise prove sterile ( ie , bilateral tubal ligation surgery least 1 month prior dose , total hysterectomy , bilateral oophorectomy surgery least 1 month prior dose ) . All woman reproductive potential use hormonal contraceptive must stable dose hormonal contraceptive product least 4 week prior dose must continue use contraceptive study . Females childbearing potential must willing use contraception ( describe ) duration study 120 day last dose 120 day study drug discontinuation . 13 . Male participant partner woman childbearing potential must use condom + spermicide female partner childbearing potential must use highly effective method contraception ( see method describe Inclusion Criterion # 12 ) begin least 1 menstrual cycle prior start study drug ( ) , throughout entire study period , 120 day last dose study drug , unless male participant totally sexually abstinent undergone successful vasectomy confirm azoospermia unless female partner sterilize surgically otherwise proven sterile . 14 . Voluntary agreement provide write informed consent willingness ability comply aspects protocol 15 . Archival tumor tissue newly obtain biopsy must available prior first dose study drug biomarker analysis . In case archival tissue provide , participant inaccessible tumor biopsy specimen enrol without biopsy upon consultation agreement sponsor Note : In case submit unstained cut slide , freshly cut slide submit test laboratory within 14 day slide cut 1 . Prior anticancer treatment within 28 day ( 5 time halflife time , whichever short ) investigational agent within 30 day prior first dose study drug . All acute toxicity relate prior treatment must resolve Grade le equal 1 2 . Participants must recover adequately toxicity and/or complication major surgery prior start therapy 3 . Participants great 1+ proteinuria urinalysis undergo 24h urine collection quantitative assessment proteinuria . Participants urine protein great equal 1 g/24hour ineligible . 4 . Gastrointestinal malabsorption , gastrointestinal anastomosis , condition might affect absorption lenvatinib 5 . New York Heart Association congestive heart failure grade II , unstable angina , myocardial infarction within past 6 month , serious cardiac arrhythmia associate significant cardiovascular impairment within past 6 month 6 . Prolongation QTc interval great 480 msec 7 . Active hemoptysis ( bright red blood least 0.5 teaspoon ) within 3 week prior first dose study drug 8 . Active infection ( infection require systemic treatment ) 9 . Participant know positive Human Immunodeficiency Virus ( HIV ) , Hepatitis B , Hepatitis C 10 . Serious nonhealing wound , ulcer , bone fracture 11 . Known intolerance either study drug ( excipients ) 12 . History organ allograft 13 . Biologic response modifier ( eg , granulocyte colonystimulating factor ) within 4 week study entry . Chronic erythropoietin therapy permit provide dose adjustment make within 2 month first dose study treatment 14 . Any medical condition , opinion investigator , would preclude participation clinical trial 15 . Females pregnant breastfeed 16 . Excluding primary tumor lead enrollment study , active malignancy ( except definitively treat melanoma insitu , basal squamous cell carcinoma skin , carcinoma insitu bladder cervix ) within past 24 month 17 . Prior treatment lenvatinib PD1 , antiPDL1 , antiPDL2 agent , exclude melanoma NSCLC prior treatment one PD1 , antiPDL1 , antiPDL2 agent allow 18 . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose study treatment . The use physiologic dos corticosteroid ( 7.5mg/d prednisone equivalent ) may approve consultation sponsor . 19 . No active autoimmune disease require systemic treatment past 2 year ( ie , use disease modify agent , corticosteroid immunosuppressive drug ) . Replacement therapy ( eg , thyroxine , insulin , physiologic corticosteroid replacement therapy adrenal pituitary insufficiency , etc . ) consider form systemic treatment . 20 . Has history ( noninfectious ) pneumonitis require steroid current pneumonitis 21 . Has receive livevirus vaccination within 30 day plan treatment start . Seasonal flu vaccine contain live virus permit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Lenvatinib</keyword>
	<keyword>Lenvima</keyword>
	<keyword>E7080</keyword>
	<keyword>Phase 1b/2</keyword>
	<keyword>Pembrolizumab</keyword>
	<keyword>Solid tumor</keyword>
</DOC>